Prognostic factors in uterine sarcoma

被引：51

作者：

Gadducci, Angiolo ^{[1
]}

机构：

[1] Univ Pisa, Dept Procreat Med, Dept Unit Gynecol Oncol, I-56127 Pisa, Italy

来源：

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY | 2011年 / 25卷 / 06期

关键词：

uterine sarcoma; leiomyosarcoma; endometrial stromal sarcoma; undifferentiated stromal sarcoma; adenosarcoma; carcinosarcoma; ENDOMETRIAL STROMAL SARCOMA; SMOOTH-MUSCLE TUMORS; ENDOTHELIAL GROWTH-FACTOR; PROGESTERONE-RECEPTOR EXPRESSION; MIXED MESODERMAL TUMORS; LYMPH-NODE METASTASES; CELL NUCLEAR ANTIGEN; STAGE-I; CLINICOPATHOLOGICAL ANALYSIS; MULLERIAN ADENOSARCOMA;

D O I：

10.1016/j.bpobgyn.2011.06.002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 [妇产科学];

摘要：

Uterine sarcomas usually have an aggressive clinical behaviour, with great tendency to local and distant spread, with unfavourable clinical outcome, excluding endometrial stromal sarcomas and adenosarcoma. Tumour stage is the strongest prognostic factor for all uterine sarcomas, with 5-year survival of about 50-55% for stage I and 8-12% for more advanced stages. Multivariate analysis of some studies have shown that women with leiomyosarcoma have a poorer survival than those with carcinosarcoma. The key issues that will be discussed include the prognostic relevance of pathological and biological variables other than tumour stage in the different histological subtypes of uterine sarcoma. Immunomarkers for cell proliferation and apoptosis have been tested for the identification of tumours with different clinical behaviour, but they are still subject to research and are not currently used in clinical practice. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：783 / 795

页数：13

共 107 条

[1]

Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients [J].